Free Trial

Tilray (TLRY) Competitors

$1.66
-0.03 (-1.78%)
(As of 06/21/2024 09:00 PM ET)

TLRY vs. CRON, USNA, CGC, MNMD, BTMD, ACB, CDXC, FOMX, MDWD, and FTLF

Should you be buying Tilray stock or one of its competitors? The main competitors of Tilray include Cronos Group (CRON), USANA Health Sciences (USNA), Canopy Growth (CGC), Mind Medicine (MindMed) (MNMD), biote (BTMD), Aurora Cannabis (ACB), ChromaDex (CDXC), Menlo Therapeutics (FOMX), MediWound (MDWD), and FitLife Brands (FTLF).

Tilray vs.

Cronos Group (NASDAQ:CRON) and Tilray (NASDAQ:TLRY) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, community ranking, earnings, profitability, valuation, dividends and institutional ownership.

Cronos Group has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. Comparatively, Tilray has a beta of 2.25, indicating that its stock price is 125% more volatile than the S&P 500.

Cronos Group has higher earnings, but lower revenue than Tilray. Cronos Group is trading at a lower price-to-earnings ratio than Tilray, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cronos Group$87.24M10.20-$73.96M-$0.15-15.53
Tilray$627.12M2.05-$1.45B-$0.44-3.77

In the previous week, Tilray had 3 more articles in the media than Cronos Group. MarketBeat recorded 9 mentions for Tilray and 6 mentions for Cronos Group. Tilray's average media sentiment score of 0.81 beat Cronos Group's score of 0.38 indicating that Cronos Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cronos Group
3 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Tilray
2 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

8.7% of Cronos Group shares are held by institutional investors. Comparatively, 9.4% of Tilray shares are held by institutional investors. 6.9% of Cronos Group shares are held by company insiders. Comparatively, 0.7% of Tilray shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Cronos Group received 17 more outperform votes than Tilray when rated by MarketBeat users. Likewise, 61.13% of users gave Cronos Group an outperform vote while only 59.28% of users gave Tilray an outperform vote.

CompanyUnderperformOutperform
Cronos GroupOutperform Votes
464
61.13%
Underperform Votes
295
38.87%
TilrayOutperform Votes
447
59.28%
Underperform Votes
307
40.72%

Tilray has a net margin of -43.98% compared to Tilray's net margin of -61.31%. Cronos Group's return on equity of -2.68% beat Tilray's return on equity.

Company Net Margins Return on Equity Return on Assets
Cronos Group-61.31% -3.06% -2.97%
Tilray -43.98%-2.68%-2.09%

Cronos Group currently has a consensus target price of $3.00, suggesting a potential upside of 28.76%. Tilray has a consensus target price of $2.71, suggesting a potential upside of 63.15%. Given Cronos Group's stronger consensus rating and higher possible upside, analysts plainly believe Tilray is more favorable than Cronos Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cronos Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Tilray
0 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.25

Summary

Tilray beats Cronos Group on 11 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLRY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TLRY vs. The Competition

MetricTilrayMedicinals & botanicals IndustryStaples SectorNASDAQ Exchange
Market Cap$1.28B$1.15B$13.99B$8.38B
Dividend YieldN/AN/A2.77%4.09%
P/E Ratio-3.778.0321.9018.02
Price / Sales2.053.20109.3265.86
Price / Cash1,861.97157.0632.0531.82
Price / Book0.331.926.024.39
Net Income-$1.45B-$103.28M$560.16M$214.83M
7 Day Performance-1.78%12.56%2.78%2.65%
1 Month Performance-10.27%1.78%0.44%-0.30%
1 Year Performance9.21%1.48%-2.16%1.53%

Tilray Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRON
Cronos Group
1.3887 of 5 stars
$2.31
-1.3%
$3.00
+29.9%
+28.7%$882.44M$87.24M-15.40356Positive News
USNA
USANA Health Sciences
2.8123 of 5 stars
$45.44
-0.6%
$46.00
+1.2%
-25.4%$865.63M$921.01M14.161,800
CGC
Canopy Growth
0.4776 of 5 stars
$7.09
-1.8%
$4.87
-31.4%
+32.4%$540.26M$220.27M-1.111,029Positive News
MNMD
Mind Medicine (MindMed)
2.0188 of 5 stars
$7.32
-2.1%
$20.00
+173.2%
+123.0%$514.38MN/A-2.4957Analyst Forecast
News Coverage
BTMD
biote
1.8279 of 5 stars
$6.55
-1.5%
$8.11
+23.8%
+11.3%$406.36M$185.36M59.55194Analyst Revision
News Coverage
High Trading Volume
ACB
Aurora Cannabis
0.4004 of 5 stars
$5.72
-0.7%
N/A-7.7%$312.03M$174.88M-1.971,130Analyst Revision
CDXC
ChromaDex
3.5521 of 5 stars
$2.75
-7.1%
$6.00
+118.2%
+66.5%$207.74M$83.57M-55.00106
FOMX
Menlo Therapeutics
0 of 5 stars
$2.99
flat
N/AN/A$184.12M$3.60M-2.3080
MDWD
MediWound
0.7522 of 5 stars
$14.59
-3.6%
$32.00
+119.3%
+29.4%$135.40M$18.69M-10.57100News Coverage
FTLF
FitLife Brands
0 of 5 stars
$27.34
-0.1%
N/A+104.0%$125.76M$52.70M18.4737

Related Companies and Tools

This page (NASDAQ:TLRY) was last updated on 6/24/2024 by MarketBeat.com Staff

From Our Partners